X
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
0
Australia
South Africa
0
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
The collaboration aims to support the Biocon for the commercialization of ACTIBLOK IPR 25 (metoprolol succinate). It is an approved product indicated for the treatment of hypertension and angina pectoris.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ACTIBLOK IPR 25
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Eris Pharmaceuticals
Deal Size: $150.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration March 13, 2024
Details:
TOPROL-XL®, is a cardioselective beta-blocker indicated for the treatment of hypertension, alone or in combination with other antihypertensives; the long-term treatment of angina pectoris; and the treatment of stable, symptomatic, heart failure of specific origins.
Lead Product(s): Metoprolol Succinate
Therapeutic Area: Cardiology/Vascular Diseases Product Name: Toprol-XL
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Melinta Therapeutics
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition April 06, 2022
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
